https://orcid.org/0000-0001-8790-7112
Abstract
The last decade has seen the introduction of 2 new licensed therapies for thrombotic thrombocytopenic purpura (TTP), caplacizumab and recombinant ADAMTS13 (rADAMTS13), for immune and congenital TTP (cTTP), respectively. They improve acute TTP outcomes, and reduce the need for plasma therapy, time to clinical response, and treatment burden. Future pathways need to replace plasma exchange in acute TTP and optimize/personalize rADAMTS13 in cTTP. Future emphasis should focus on additional monoclonals/treatments to tackle ADAMTS13 antibodies.
References
1.
Moschcowitz
ELI
. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease
. Proc NY Pathol Soc
. 1924
;24
:21
-24
.2.
Cataland
SR
, Coppo
P
, Scully
M
, Lämmle
B
. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
. Blood
. 2024
;144
(11
):1143
-1152
.3.
Moake
JL
, Rudy
CK
, Troll
JH
, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
. N Engl J Med
. 1982
;307
(23
):1432
-1435
.4.
Rock
GA
, Shumak
KH
, Buskard
NA
, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group
. N Engl J Med
. 1991
;325
(6
):393
-397
.5.
Bell
WR
, Braine
HG
, Ness
PM
, Kickler
TS
. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients
. N Engl J Med
. 1991
;325
(6
):398
-403
.6.
Furlan
M
, Robles
R
, Solenthaler
M
, Wassmer
M
, Sandoz
P
, Lammle
B
. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
. Blood
. 1997
;89
(9
):3097
-3103
.7.
Tsai
HM
, Lian
EC
. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
. N Engl J Med
. 1998
;339
(22
):1585
-1594
.8.
Levy
GG
, Nichols
WC
, Lian
EC
, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
. Nature
. 2001
;413
(6855
):488
-494
.9.
Chemnitz
J
, Draube
A
, Scheid
C
, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab
. Am J Hematol
. 2002
;71
(2
):105
-108
.10.
Scully
M
, Cohen
H
, Cavenagh
J
, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13
. Br J Haematol
. 2007
;136
(3
):451
-461
.11.
Scully
M
, McDonald
V
, Cavenagh
J
, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
. Blood
. 2011
;118
(7
):1746
-1753
.12.
Bull
TP
, McCulloch
R
, Nicolson
PL
, et al. Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019
. J Thromb Haemost
. 2022
;20
(6
):1428
-1436
.13.
Alwan
F
, Vendramin
C
, Vanhoorelbeke
K
, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura
. Blood
. 2017
;130
(4
):466
-471
.14.
Peyvandi
F
, Scully
M
, Kremer Hovinga
JA
, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura
. N Engl J Med
. 2016
;374
(6
):511
-522
.15.
Scully
M
, Knöbl
P
, Kentouche
K
, et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
. Blood
. 2017
;130
(19
):2055
-2063
.16.
Sargentini-Maier
ML
, De Decker
P
, Tersteeg
C
, Canvin
J
, Callewaert
F
, De Winter
H
. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura
. Expert Rev Clin Pharmacol
. 2019
;12
(6
):537
-545
.17.
Peyvandi
F
, Scully
M
, Kremer Hovinga
JA
, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura
. J Thromb Haemost
. 2017
;15
(7
):1448
-1452
.18.
Scully
M
, Cataland
SR
, Peyvandi
F
, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
. N Engl J Med
. 2019
;380
(4
):335
-346
.19.
Del Río-Garma
J
, Bobillo
S
, de la Rubia
J
, et al. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era
. Ann Hematol
. 2022
;101
(1
):59
-67
.20.
Izquierdo
CP
, Mingot-Castellano
ME
, Fuentes
AEK
, et al. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
. Blood Adv
. 2022
;6
(24
):6219
-6227
.21.
Knoebl
P
, Cataland
S
, Peyvandi
F
, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
. J Thromb Haemost
. 2020
;18
(2
):479
-484
.22.
Bowyer
A
, Brown
P
, Hopkins
B
, et al. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab
. Br J Haematol
. 2022
;197
(3
):349
-358
.23.
Bergstrand
M
, Hansson
E
, Delaey
B
, Callewaert
F
, De Passos Sousa
R
, Sargentini-Maier
ML
. Caplacizumab model-based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura
. J Clin Pharmacol
. 2022
;62
(3
):409
-421
.24.
Boberg
E
, Kimiaei
A
, Karlström
C
, Ljungqvist
M
, Ågren
A
, Bruzelius
M
. Iatrogenic hemorrhage and extensive venous thromboembolism during iTTP treatment with caplacizumab-a case report
. EJHaem
. 2024
;5
(4
):768
-771
.25.
Scully
M
, Rayment
R
, Clark
A
, et al. A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies
. Br J Haematol
. 2023
;203
(4
):546
-563
.26.
Cuker
A
, Cataland
SR
, Coppo
P
, et al. Redefining outcomes in immune TTP: an international working group consensus report
. Blood
. 2021
;137
(14
):1855
-1861
.27.
Prasannan
N
, Thomas
M
, Stubbs
M
, et al. Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era
. Blood
. 2023
;141
(18
):2206
-2213
.28.
Saito
K
, Sakai
K
, Kubo
M
, et al. Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP
. Blood Adv
. 2024
;8
(9
):2151
-2159
.29.
Mingot-Castellano
ME
, García-Candel
F
, Martínez-Nieto
J
, et al. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
. Blood
. 2024
;143
(18
):1807
-1815
.30.
Dutt
T
, Shaw
RJ
, Stubbs
M
, et al. Real-world experience with caplacizumab in the management of acute TTP
. Blood
. 2021
;137
(13
):1731
-1740
.31.
Gavriilaki
E
, Nikolousis
E
, Koravou
EE
, et al. Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
. Front Med
. 2023
;10
:1226114
.32.
Völker
LA
, Kaufeld
J
, Miesbach
W
, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
. Blood Adv
. 2020
;4
(13
):3085
-3092
.33.
de Oliveira Boechat
T
, de Holanda Farias
JS
, Ribeiro
EFO
, de Andrade
MLL
. Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
. Ann Hematol
. 2023
;102
(6
):1581
-1588
.34.
Chander
DP
, Loch
MM
, Cataland
SR
, George
JN
. Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura
. N Engl J Med
. 2019
;381
(1
):92
-94
.35.
Kühne
L
, Knöbl
P
, Eller
K
, et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
. Blood
. 2024
;144
(14
):1486
-1495
.36.
Cid
J
, Lozano
M
. Caplacizumab as frontline therapy in addition to standard treatment in iTTP
. Blood Adv
. 2023
;7
(10
):2129
-2131
.37.
Peyvandi
F
, Cataland
S
, Scully
M
, et al. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
. Blood Adv
. 2021
;5
(8
):2137
-2141
.38.
Kühne
L
, Kaufeld
J
, Völker
LA
, et al. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
. J Thromb Haemost
. 2022
;20
(4
):951
-960
.39.
Camilleri
RS
, Scully
M
, Thomas
M
, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom
. J Thromb Haemost
. 2012
;10
(9
):1792
-1801
.40.
Lotta
LA
, Wu
HM
, Mackie
IJ
, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura
. Blood
. 2012
;120
(2
):440
-448
.41.
Alwan
F
, Vendramin
C
, Liesner
R
, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura
. Blood
. 2019
;133
(15
):1644
-1651
.42.
van Dorland
HA
, Taleghani
MM
, Sakai
K
, et al. The international Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrolment until 2017
. Haematologica
. 2019
;104
(10
):2107
-2115
.43.
Tarasco
E
, Bütikofer
L
, Friedman
KD
, et al. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura
. Blood
. 2021
;137
(25
):3563
-3575
.44.
Taylor
A
, Vendramin
C
, Oosterholt
S
, Della Pasqua
O
, Scully
M
. Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura
. J Thromb Haemost
. 2019
;17
(1
):88
-98
.45.
Furlan
M
, Robles
R
, Morselli
B
, Sandoz
P
, Lammle
B
. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura
. Thromb Haemost
. 1999
;81
(1
):8
-13
.46.
Scully
M
, Antun
A
, Cataland
SR
, et al. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
. N Engl J Med
. 2024
;390
(17
):1584
-1596
.47.
Marie Scully
JB
, Bhattacharya
Indranil
, Cataland
Spero
, et al. Phase 2 randomized, placebo-controlled, double-blind, multicenter study of recombinant ADAMTS13 in patients with immune-mediated thrombotic thrombocytopenic purpura [abstract]
. Hemasphere
. 2023
;7
(suppl
):e8651306
.48.
Siddiqui
A
, Journeycake
JM
, Borogovac
A
, George
JN
. Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children
. Pediatr Blood Cancer
. 2021
;68
(5
):e28949
.49.
Taylor
A
, Keogh
L
, Dickens
E
, et al. Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience
. Blood Adv
. 2024
;8
(17
):4563
-4567
.50.
Stubbs
MJ
, Kendall
G
, Scully
M
. Recombinant ADAMTS13 in severe neonatal thrombotic thrombocytopenic purpura
. N Engl J Med
. 2022
;387
(25
):2391
-2392
.51.
Asmis
LM
, Serra
A
, Krafft
A
, et al. Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura
. N Engl J Med
. 2022
;387
(25
):2356
-2361
.52.
Dadoun
SE
, Adam
K
, Hensch
L
, et al. Recombinant ADAMTS13: an effective rescue therapy for acute cTTP during pregnancy
. Blood Adv
. 2024
;8
(14
):3718
-3720
.53.
Schimmer
RR
, Sutter
T
, Bachofner
A
, et al. Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab
. Br J Haematol
. 2024
;204
(5
):1994
-1998
.54.
Kühne
L
, Völker
LA
, Hagmann
H
, et al. First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy
. Br J Haematol
. 2022
;196
(3
):e30
-e33
.55.
Bruzzese
A
, Vigna
E
, Martino
EA
, et al. Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period
. Blood Coagul Fibrinolysis
. 2023
;34
(3
):215
-217
.56.
Odetola
O
, Martin
KA
, Dreyer
M
, Rajan
P
, Zakarija
A
, Stein
BL
. A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura
. Br J Haematol
. 2023
;202
(4
):879
-882
.57.
Alwan
F
, Vendramin
C
, Budde
U
, et al. Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura
. EJHaem
. 2021
;2
(2
):188
-195
.58.
Dekimpe
C
, Roose
E
, Sakai
K
, Tersteeg
C
, De Meyer
SF
, Vanhoorelbeke
K
. Toward gene therapy for congenital thrombotic thrombocytopenic purpura
. J Thromb Haemost
. 2023
;21
(5
):1090
-1099
.59.
Doyle
AJ
, Stubbs
MJ
, Lester
W
, et al. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura
. Br J Haematol
. 2022
;198
(2
):391
-396
.60.
Mackensen
A
, Müller
F
, Mougiakakos
D
, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
. Nat Med
. 2022
;28
(10
):2124
-2132
.61.
Müller
F
, Taubmann
J
, Bucci
L
, et al. CD19 CAR T-cell therapy in autoimmune disease-a case series with follow-up
. N Engl J Med
. 2024
;390
(8
):687
-700
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal